Making the COVID-19 Oral Treatment: How 2,000+ Pfizer Team Members Made It Happen
As the potential threat of COVID-19 became clear by early 2020, teams across Pfizer sprang into action. Together, they worked to better understand the novel virus.
with prespecified serotype-specific IgG concentrations and IgG Geometric Means Concentrations …
ordered multimers of normal human IgG Fc to its receptors. About Gliknik …
fully human anti-PD-L1 IgG1 monoclonal antibody that fully human anti-PD-L1 IgG1 monoclonal antibody. By …
fully human anti-PD-L1 IgG1 monoclonal antibody that is being fully human anti-PD-L1 IgG1 monoclonal antibody. By …
fully human anti-PD-L1 IgG1 monoclonal antibody, Breakthrough fully human anti-PD-L1 IgG1 monoclonal antibody. By …
fully human anti-PD-L1 IgG1 monoclonal antibody, pending an fully human anti-PD-L1 IgG1 monoclonal antibody. By …
fully human anti-PD-L1 IgG1 monoclonal antibody, in treating fully human anti-PD-L1 IgG1 monoclonal antibody. By …
fully human anti-PD-L1 IgG1 monoclonal antibody. By fully human anti-PD-L1 IgG1 monoclonal antibody. By …
fully human anti-PD-L1 IgG1 monoclonal antibody, Fast Track fully human anti-PD-L1 IgG1 monoclonal antibody. By …
fully human anti-PD-L1 IgG1 monoclonal antibody and could be fully human anti-PD-L1 IgG1 monoclonal antibody. By …
Behind the Science Features
Press Releases
06.17.2022
06.15.2022
06.14.2022
06.13.2022
06.09.2022
06.09.2022
06.08.2022
06.06.2022
06.05.2022
06.05.2022
06.04.2022
06.02.2022
Media Resources
This information is intended for media professionals. To ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may only respond to calls and emails from professional journalists.
Clinical Trials
Our Careers